ISSN: 1305-3876
Dil: Türkçe
Hakkında: Özel sayılar şeklinde yayınlanır.
|
|
|
Febril Neutropenia
Dr. Mustafa YAYLACIa
aTıbbi Onkoloji Kliniği, Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, İSTANBUL
Despite improvements in long term survival, infections remains an important complication of cancer therapy and accounts for the majority of chemotherapy associated deaths, especially when the administration of proper antibiotics is delayed. Frequent changing patterns of infection and antibiotic resistance trends don’t allow the development of treatment guidelence. Early initiation of antibiotics remains the gold standart. Single broad spectrum antibiotics has replaced the classical combination therapy. Without documentation of gram positive microorganisms empirical administration of vancomycin isn’t favored. Risk estimation models were developed for the identification of patients who are suitable for outpatients treatment. Despite an appropriate initial regimen and resolution of neutropenia isn’t imminent, antifungal therapy should be started if there is no clinical improvement. Prophylactic granulocyte colony stimulating factor can be given in case of delaying chemotherapy negatively effect cure rate, overall or disease free survival. Colony stimulating factors can be administrated as a part of febrile neutropenic treatment in high risk patients with hypotension, pneumonia, cellulitis or fungal infections.Keywords: Febrile, neutopenia, cancerTurkiye Klinikleri J Surg Med Sci 2006, 2(33):45-48
|
|
|
|
|
